Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Dr. Pavlick on the COLUMBUS Trial in Metastatic Melanoma

May 1st 2020

Anna C. Pavlick, DO, discusses updated results from the COLUMBUS trial in metastatic melanoma.

Dr. Algazi on Benefit of Continuous Dabrafenib/Trametinib Dosing in BRAF+ Melanoma

April 30th 2020

Alain Algazi, MD, discusses the benefit of continuous dosing with dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF mutation–positive advanced melanoma.

Dr. Kudchadkar on the Biological Differences Between Ocular and Cutaneous Melanoma

April 29th 2020

Ragini R. Kudchadkar, MD, discusses the biological differences between ocular melanoma and cutaneous melanoma.

Atezolizumab Plus Vemurafenib/Cobimetinib Impresses in BRAF V600+ Melanoma

April 28th 2020

Treatment with atezolizumab in combination with vemurafenib and cobimetinib was found to significantly improve progression-free survival and produce durable responses versus vemurafenib and cobimetinib alone in treatment-naïve patients with BRAF V600–mutant advanced melanoma.

Continuous Dabrafenib/Trametinib Dosing Improves PFS in BRAF+ Melanoma

April 27th 2020

Continuous dosing with dabrafenib and trametinib improved progression-free survival compared with intermittent dosing in patients with BRAF mutation–positive advanced melanoma.

Novel Therapies Expand Options in Melanoma, But Surgery Retains Role

April 16th 2020

Omid Hamid, MD, discusses emerging treatment approaches, the role of surgery, and ongoing research efforts in melanoma.

Study Tests Novel Doublet Designed to Promote Immunity in cSCC

April 13th 2020

Investigators are testing the hypothesis that administering cetuximab with an anti–PD-L1 agent will induce immunostimulatory synergy and prolong survival in patients with cutaneous squamous cell carcinoma.

T-Cell Therapies Spark Interest in Melanoma, Despite Clinical Challenges

April 11th 2020

Jason J. Luke, MD, FACP, discusses the future of T-cell therapies in melanoma, emerging biomarkers, and ongoing research regarding the gut microbiome.

Ongoing Research Efforts in Metastatic Ocular Melanoma Could Shift Paradigm

April 11th 2020

Ragini Kudchadkar, MD, discusses the prognosis of patients with metastatic ocular melanoma and the work being done to define novel approaches in melanoma.

Dr. Hamid on Promising Triplet Combinations Under Exploration in Melanoma

April 11th 2020

Omid Hamid, MD, discusses promising triplet combination under exploration in melanoma.

STP705 Shows Promise in Cutaneous Squamous Cell Carcinoma

April 10th 2020

STP705 met the primary efficacy end point in an ongoing phase II study of patients with cutaneous squamous cell carcinoma in situ.

Lifirafenib Active in Melanoma, Other Solid Tumors

April 9th 2020

The investigational RAF inhibitor lifirafenib demonstrated antitumor activity in patients with melanoma and other solid tumors.

Dr. Pavlick on Sequencing Challenges in BRAF-Mutant Melanoma Treatment

March 31st 2020

Anna C. Pavlick, DO, discusses sequencing challenges faced in the treatment of patients with BRAF-mutant melanoma.

Using Steroids to Manage Immunotherapy-Associated AEs in Melanoma

March 30th 2020

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses how to judiciously use steroids to manage adverse events in patients with melanoma who are receiving immunotherapy.

Dr. Polsky on the Clinical Validity of ctDNA in BRAF-Mutant Melanoma

March 23rd 2020

David Polsky, MD, PhD, discusses the use of circulating tumor DNA (ctDNA) in the COMBI-d trial on melanoma.

John Theurer Cancer Center Evaluating Personalized Cancer Vaccine in High-Risk Melanoma

March 4th 2020

An ongoing clinical trial will assess whether the adjuvant combination of the personalized cancer vaccine mRNA-4157 and pembrolizumab improves recurrence-free survival compared with pembrolizumab alone in patients with complete resection of cutaneous melanoma and a high-risk of recurrence.

Dr. Liebman on the Use of Digital Surveillance in Melanoma

February 28th 2020

Tracey Liebman, MD, discusses the use of digital surveillance in melanoma.

Dr. Shapiro on the Surgical Management of Advanced-Stage Melanoma

February 28th 2020

Richard L. Shapiro, MD, discusses the surgical management of advanced-stage melanoma.

Dr. Weber on Emerging Immunotherapy Combinations in Melanoma

February 19th 2020

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the melanoma program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses emerging immunotherapy combinations in melanoma.

Adjuvant Ipilimumab Improves OS in High-Risk Melanoma

February 18th 2020

Adjuvant treatment with ipilimumab, when given at a 3-mg/kg dose, was found to improve overall survival compared with high-dose interferon alfa in patients with high-risk melanoma.